GHRP (Growth Hormone Releasing Peptide)
Definition
A class of synthetic peptides that stimulate growth hormone release by activating the ghrelin receptor (GHS-R1a). Includes GHRP-2, GHRP-6, hexarelin, and ipamorelin. Each variant has different potency and side-effect profiles regarding hunger, cortisol, and prolactin.
What this means for research sourcing
Mechanistic terms like this describe how research compounds behave in vitro. See the mechanism overviews for compounds Volta stocks.
Related research compounds at Volta Peptides
Compounds referenced in this definition that Volta supplies for in vitro research use, each ≥98% HPLC-verified with a certificate of analysis.
For in vitro research use only. Not for human consumption.
Related Terms in Pharmacology
Bioavailability
The proportion of a substance that enters the circulation when introduced into the body and is able to have an active effect. Different administration routes affect bioavailability.
Half-Life
The time required for the concentration of a substance in the body to decrease by half. Determines dosing frequency and accumulation patterns.
Pharmacokinetics
The study of how a drug moves through the body — absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics
The study of what a drug does to the body — its mechanism of action, therapeutic effects, and dose-response relationships. Complementary to pharmacokinetics.
First-Pass Metabolism
The phenomenon where a drug is metabolized by the liver before reaching systemic circulation, significantly reducing bioavailability. This is a primary reason most peptides are administered by injection rather than orally.
Receptor Agonist
A substance that binds to a receptor and activates it, mimicking the action of a naturally occurring substance. Many therapeutic peptides are receptor agonists.
Receptor Antagonist
A substance that binds to a receptor and blocks its activation, preventing the natural ligand from exerting its effect.
Desensitization
A reduction in receptor response after prolonged or repeated exposure to an agonist. Can lead to reduced effectiveness of some peptides over time.